

Supplementary Table S1. Neuropathic findings.

Treatment n (%)	Mucocutaneous BD (n=69)	Ocular BD (n=26)	Vascular BD (n=40)	Neuro-BD (n=17)	FMF (n=37)	Healthy controls (n=29)	p-value
Neuropathic symptoms	33 (47.8)	14 (53.8)	21 (52.5)	8 (47.1)	17 (46.0)	6 (20.7)	0.177
Localisation of neuropathic symptoms							
Symmetrical	25 (75.8)	10 (71.4)	16 (76.2)	5 (62.5)	13 (76.5)	6 (100.0)	0.525
Asymmetrical	8 (24.2)	4 (28.6)	5 (25.8)	3 (37.5)	4 (23.5)	0	
Right lower distal	23 (69.7)	6 (42.9)	12 (57.1)	8 (100.0)	9 (52.9)	4 (66.7)	0.270
Right lower proximal	2 (6.1)	2 (14.3)	2 (9.5)	2 (25.0)	0	0	0.391
Right upper distal	14 (42.4)	7 (50.0)	10 (47.6)	3 (37.5)	7 (41.2)	3 (50.0)	0.977
Right upper proximal	3 (9.1)	4 (28.6)	6 (28.6)	0	1 (5.9)	0	0.058
Left lower distal	20 (60.6)	7 (50.0)	11 (52.4)	7 (87.5)	9 (52.9)	4 (66.7)	0.748
Left lower proximal	0	2 (14.3)	1 (4.8)	2 (25.0)	0	0	0.053
Left upper distal	16 (48.5)	6 (42.9)	7 (31.8)	2 (25.0)	7 (41.2)	3 (50.0)	0.662
Left upper proximal	2 (6.1)	4 (28.6)	4 (19.0)	0	1 (5.9)	0	0.133
EMG study							
Results of EMG							
Mononeuritis multiplex	1 (12.5)	0	1 (14.3)	0	0	0	0.553
Sensorineural injury	2 (25.0)	0	0	1 (33.3)	3 (30.0)	1 (50.0)	
Polyradiculopathy	1 (12.5)	0	0	0	1 (10.0)	0	
Normal	4 (50.0)	2 (100.0)	6 (85.7)	2 (66.7)	6 (60.0)	1 (50.0)	

Supplementary Table S2. Frequency of treatment agents used in overall follow-up.

Treatment n (%)	Mucocutaneous BD (n=69)	Ocular BD (n=26)	Vascular BD (n=40)	Neuro-BD (n=17)	FMF (n=37)	Healthy controls (n=29)	p-value
Colchicine	62 (89.9)	20 (76.9)	30 (75.0)	9 (52.9)	36 (97.3)	0	<0.001
Azathioprine	19 (27.5)	22 (84.6)	36 (90.0)	15 (88.2)	0	1 (3.4)	<0.001
Corticosteroids	34 (49.3)	23 (88.5)	35 (87.5)	16 (94.1)	4 (10.8)	0	<0.001
Infliximab	1 (1.4)	2 (7.7)	12 (30.0)	8 (47.1)	0	0	<0.001
Adalimumab	5 (7.2)	10 (38.5)	5 (12.5)	5 (29.4)	0	0	<0.001
Cyclophosphamide	2 (2.9)	1 (3.8)	9 (22.5)	1 (5.9)	0	0	<0.001
ASA	8 (11.6)	3 (11.5)	8 (20.0)	4 (23.5)	0	1 (3.4)	<0.001
LMWH	1 (1.4)	0	5 (12.5)	2 (11.8)	0	0	<0.001
DOAC	0	0	7 (17.5)	1 (5.9)	0	0	<0.001
Warfarin	0	0	3 (7.5)	1 (5.9)	0	0	<0.001
NSAID	25 (36.2)	9 (34.6)	18 (45.0)	8 (47.1)	1 (2.7)	0	<0.001
CSA	1 (1.5)	2 (7.7)	1 (2.5)	1 (5.9)	0	0	0.297

BD: Behçet's disease; FMF: familial Mediterranean fever; DOAC: direct oral anticoagulant; ASA: acetylsalicylic acid; NSAID: non-steroidal anti-inflammatory drug; LMWH: low molecular weight heparin; CSA: cyclosporine.

Supplementary Table S3. Frequency of treatment agents used at visit of study assessment.

Treatment n (%)	Mucocutaneous BD (n=69)	Ocular BD (n=26)	Vascular BD (n=40)	Neuro-BD (n=17)	FMF (n=37)	Healthy controls (n=29)	p-value
Colchicine	54 (78.3)	13 (50.0)	15 (37.5)	3 (17.6)	31 (83.8)	0	<0.001
Azathioprine	14 (20.3)	16 (61.5)	23 (57.5)	10 (58.8)	0 (0)	0	<0.001
Corticosteroids	12 (17.6)	7 (26.9)	21 (52.5)	9 (53.0)	0 (0)	0	<0.001
Infliximab	0	2 (7.7)	10 (25.0)	7 (43.8)	0	0	<0.001
Adalimumab	3 (4.2)	6 (23.1)	2 (5.0)	3 (17.6)	0	0	<0.001
Cyclophosphamide	0 (0)	0 (0)	1 (2.5)	1 (5.9)	0 (0)	0	0.206
ASA	8 (11.6)	3 (11.5)	8 (20.0)	4 (23.5)	0 (0)	1 (3.4)	0.031
LMWH	1 (1.4)	0 (0)	5 (12.5)	2 (11.8)	0 (0)	0	0.006
DOAC	0 (0)	0 (0)	7 (17.5)	1 (5.9)	0 (0)	0	<0.001
Warfarin	0 (0)	0 (0)	3 (7.5)	1 (5.9)	0 (0)	0	0.039
NSAID	4 (5.8)	3 (11.5)	5 (12.5)	0 (0)	0 (0)	0	0.018
CSA	0	1 (3.8)	0	0	0	0	0.510

BD: Behçet's disease; FMF: familial Mediterranean fever; DOAC: direct oral anticoagulant; ASA: Acetylsalicylic acid; NSAID: non-steroidal anti-inflammatory drug; LMWH: low molecular weight heparin; CSA: cyclosporine.

Supplementary Table S4. Use of imaging techniques and frequency of pathologic findings.

Treatment n (%)	Mucocutaneous BD (n=69)	Ocular BD (n=26)	Vascular BD (n=40)	Neuro-BD (n=17)	FMF (n=37)	Healthy controls (n=29)	p-value
Cranial CT	8 (11.6)	5 (19.2)	13 (32.5)	6 (35.3)	6 (16.2)	4 (13.8)	0.058
Pathologic cranial CT findings	1 (12.5)	0	0	0	0	0	0.677
Cranial MRI	17 (24.6)	11 (42.3)	20 (50.0)	16 (94.1)	9 (24.3)	5 (17.2)	<0.001
Pathologic cranial MRI findings	3 (17.6)	0	0	10 (62.5)	0	0	<0.001
MR venography	7 (10.1)	7 (26.9)	12 (30.0)	15 (88.2)	0	0	<0.001
Pathologic MR venography findings	0	0	0	9 (60.0)	0	0	0.002

ùBD: Behçet's disease; FMF: familial Mediterranean fever; CT: computed tomography; MRI: magnetic resonance imaging.

Supplementary Table S5. Detailed components of neurologic examination.

Neurologic examination components n, (%)	Mucocutaneous BD (n=69)	Ocular BD (n=26)	Vascular BD (n=40)	Neuro-BD (n=17)	FMF (n=37)	Healthy controls (n=29)	p-value
Right eye examination							
Normal	69 (100)	24 (92.3)	40 (100)	13 (76.5)	37 (100)	29 (100)	0.037
Light perception	0	1 (3.8)	0	2 (11.8)	0	0	
Motion perception	0	0	0	2 (11.8)	0	0	
Finger counting	0	1 (3.8)	0	0	0	0	
Total vision loss	0	0	0	0	0	0	
Left eye examination							
Normal	69 (100)	24 (92.3)	40 (100)	16 (94.1)	37 (100)	29 (100)	0.357
Light perception	0	1 (3.8)	0	0	0	0	
Motion perception	0	0	0	0	0	0	
Finger counting	0	0	0	0	0	0	
Total vision loss	0	1 (3.8)	0	0	0	0	
Other domains							
Horizontal nystagmus	1 (1.4)	1 (3.8)	0	1 (5.9)	0	0	0.393
Facial asymmetry	0	0	1 (2.5)	0	0	0	0.957
Tongue deviation	1 (1.4)	0	0	0	0	0	0.825
Dysphagia	7 (10.1)	2 (7.7)	7 (17.5)	2 (11.8)	2 (5.4)	0	0.098
Motor deficit	0	0	0	1 (5.9)	0	0	0.631
Muscle atrophy	0	0	0	0	1 (2.7)	0	0.613
Abnormal muscle tone	0	0	0	0	0	0	N/A
Anal incontinence	1 (1.4)	0	1 (2.5)	0	0	1 (3.4)	0.674
Urinary incontinence	13 (18.8)	4 (15.4)	3 (7.5)	3 (17.6)	6 (16.2)	2 (6.9)	0.510
Failed tandem walk	4 (5.9)	4 (15.4)	3 (7.5)	2 (11.8)	2 (5.4)	1 (3.4)	0.548
Failed finger to nose	0	1 (3.8)	0	0	0	0	0.557
Failed dysidiadochokinesia	0	1 (3.8)	0	1 (5.9)	0	0	0.247
Postural instability	0	1 (3.8)	0	0	0	0	0.557
Failed sit to stand test	3 (4.3)	0	7 (17.5)	2 (11.8)	1 (2.7)	1 (3.4)	0.035
Painful upper extremity	0	0	0	1 (5.9)	0	0	0.631
Painful lower extremity	0	0	1 (2.5)	1 (5.9)	0	0	0.763
Impaired touch sensation in upper extremity	0	0	0	1 (5.9)	0	0	0.631
Impaired touch sensation in lower extremity	1 (1.4)	0	1 (2.5)	1 (5.9)	0	0	0.512
Visual impairment	0	0	0	1 (5.9)	0	0	0.631
Repetition impairment	0	0	0	0	0	0	N/A
Naming impairment	0	0	0	0	0	0	N/A
Reading impairment	2 (2.9)	0	0	0	0	0	0.461
Writing impairment	2 (2.9)	0	0	0	0	0	0.461
Calculation impairment	2 (2.9)	0	0	0	0	0	0.461
Loss of facial expression	0	0	0	0	0	0	N/A
Motor apraxia	0	0	0	0	0	0	N/A
Constructional apraxia	1 (1.4)	0	0	0	2 (5.4)	0	0.341
Dressing apraxia	0	0	0	0	0	0	N/A
Astereognosis	0	0	0	0	0	0	N/A
Prosopagnosia	0	0	0	0	0	0	N/A
Auditory agnosia	0	0	0	0	0	0	N/A